EP 1175446 A1 20020130 - HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING
Title (en)
HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING
Title (de)
HUMANE ANTIKÖRPER, WELCHE IL-12 BINDEN UND VERFAHREN ZU DEREN HERSTELLUNG
Title (fr)
ANTICORPS HUMAINS LIANT IL-12 ET PROCEDE POUR LEUR PREPARATION
Publication
Application
Priority
- US 0007946 W 20000324
- US 12660399 P 19990325
Abstract (en)
[origin: WO0056772A1] Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the inveniton are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
IPC 1-7
C07K 16/24; C12N 15/13; C12N 15/63; C12N 5/10; C07K 16/00; A61K 39/395; G01N 33/577; C12P 21/08; A61P 43/00
IPC 8 full level
G01N 33/53 (2006.01); A61K 39/395 (2006.01); A61P 1/04 (2006.01); A61P 1/16 (2006.01); A61P 3/10 (2006.01); A61P 5/16 (2006.01); A61P 7/00 (2006.01); A61P 7/02 (2006.01); A61P 7/04 (2006.01); A61P 7/06 (2006.01); A61P 9/00 (2006.01); A61P 9/04 (2006.01); A61P 9/10 (2006.01); A61P 9/14 (2006.01); A61P 11/00 (2006.01); A61P 11/06 (2006.01); A61P 11/16 (2006.01); A61P 13/12 (2006.01); A61P 17/00 (2006.01); A61P 17/02 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 19/08 (2006.01); A61P 21/04 (2006.01); A61P 25/00 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); A61P 27/02 (2006.01); A61P 31/00 (2006.01); A61P 31/04 (2006.01); A61P 31/18 (2006.01); A61P 33/00 (2006.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); A61P 37/06 (2006.01); A61P 37/08 (2006.01); A61P 43/00 (2006.01); C07K 16/24 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 15/02 (2006.01); C12N 15/13 (2006.01); C12P 21/08 (2006.01)
CPC (source: EP KR)
A61P 1/00 (2018.01 - EP); A61P 1/04 (2018.01 - EP); A61P 1/16 (2018.01 - EP); A61P 3/10 (2018.01 - EP); A61P 5/14 (2018.01 - EP); A61P 5/16 (2018.01 - EP); A61P 7/00 (2018.01 - EP); A61P 7/02 (2018.01 - EP); A61P 7/04 (2018.01 - EP); A61P 7/06 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/04 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 9/14 (2018.01 - EP); A61P 11/00 (2018.01 - EP); A61P 11/06 (2018.01 - EP); A61P 11/08 (2018.01 - EP); A61P 11/16 (2018.01 - EP); A61P 13/12 (2018.01 - EP); A61P 17/00 (2018.01 - EP); A61P 17/02 (2018.01 - EP); A61P 17/06 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 19/08 (2018.01 - EP); A61P 21/02 (2018.01 - EP); A61P 21/04 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 25/14 (2018.01 - EP); A61P 25/16 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 27/02 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 31/00 (2018.01 - EP); A61P 31/04 (2018.01 - EP); A61P 31/18 (2018.01 - EP); A61P 33/00 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 37/00 (2018.01 - EP); A61P 37/02 (2018.01 - EP); A61P 37/04 (2018.01 - EP); A61P 37/06 (2018.01 - EP); A61P 37/08 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07K 16/00 (2013.01 - EP); C07K 16/24 (2013.01 - KR); C07K 16/244 (2013.01 - EP); A61K 2039/505 (2013.01 - EP); C07K 2317/21 (2013.01 - EP); C07K 2317/565 (2013.01 - EP); C07K 2317/622 (2013.01 - EP); C07K 2317/73 (2013.01 - EP); C07K 2317/76 (2013.01 - EP); C07K 2317/92 (2013.01 - EP)
Citation (examination)
- PINI A. ET AL: "Design and use of a phage diaplay library", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 34, 21 August 1998 (1998-08-21), USA, pages 21769 - 21776, XP002124781
- NERI D. ET AL: "Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform", NATURE BIOTECHNOLOGY, vol. 15, November 1997 (1997-11-01), UK, pages 12711275, XP002124779
- See also references of WO 0056772A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated extension state (EPC)
RO SI
DOCDB simple family (publication)
WO 0056772 A1 20000928; AR 043274 A1 20050727; AR 063780 A2 20090218; AR 094125 A2 20150715; AU 3921600 A 20001009; BG 106027 A 20020628; BG 111337 A 20130228; BG 66399 B1 20131231; BR 0009323 A 20020108; CA 2365281 A1 20000928; CA 2365281 C 20090804; CA 2669512 A1 20000928; CA 2796140 A1 20000928; CN 100439399 C 20081203; CN 101066997 A 20071107; CN 101066997 B 20130327; CN 101333256 A 20081231; CN 101921772 A 20101222; CN 101921772 B 20130327; CN 1351614 A 20020529; CY 1113326 T1 20160622; CY 2013007 I1 20200529; CZ 20013434 A3 20020814; CZ 303725 B6 20130403; DK 2168984 T3 20121210; EP 1175446 A1 20020130; EP 2168984 A1 20100331; EP 2168984 B1 20120829; EP 2301970 A1 20110330; EP 2319870 A2 20110511; EP 2319870 A3 20111026; ES 2390849 T3 20121119; HK 1142083 A1 20101126; HU P0200575 A2 20020629; HU P0200575 A3 20041129; IL 145134 A0 20020630; IL 145134 A 20101130; IL 207029 A0 20101230; JP 2002542770 A 20021217; JP 2012010702 A 20120119; JP 2014138594 A 20140731; JP 4841038 B2 20111221; KR 100818066 B1 20080331; KR 101222450 B1 20130116; KR 20020026416 A 20020410; KR 20060127247 A 20061211; KR 20100021669 A 20100225; KR 20120091477 A 20120817; KR 20130105766 A 20130925; KR 20140094647 A 20140730; LU 92159 I2 20130429; MX PA01009645 A 20030904; MY 142984 A 20110214; MY 145191 A 20111230; NO 20014605 D0 20010921; NO 20014605 L 20011126; NO 20131482 L 20011126; NO 2014024 I1 20140918; NO 334828 B1 20140610; NZ 513945 A 20010928; NZ 529571 A 20060331; NZ 592550 A 20121221; NZ 596723 A 20130726; NZ 611563 A 20150130; PL 218748 B1 20150130; PL 351842 A1 20030616; PL 409839 A1 20150330; PT 2168984 E 20120924; SI 2168984 T1 20121231; SK 13672001 A3 20020305; SK 288082 B6 20130603; TR 200102715 T2 20020923; TR 200501367 T2 20050921; TR 200503572 T2 20060421; TR 200603997 T1 20100121; TR 200802278 T2 20080821; TW 200738749 A 20071016; TW 201043639 A 20101216; TW 201215619 A 20120416; TW 201300412 A 20130101; TW I280980 B 20070511; TW I339209 B 20110321; TW I365193 B 20120601; TW I410433 B 20131001; ZA 200107774 B 20021220
DOCDB simple family (application)
US 0007946 W 20000324; AR P000101321 A 20000324; AR P070104977 A 20071108; AR P100102574 A 20100715; AU 3921600 A 20000324; BG 10602701 A 20011018; BG 11133712 A 20121108; BR 0009323 A 20000324; CA 2365281 A 20000324; CA 2669512 A 20000324; CA 2796140 A 20000324; CN 00807783 A 20000324; CN 200510128677 A 20000324; CN 200810099323 A 20000324; CN 201010195286 A 20000324; CY 121101073 T 20121112; CY 2013007 C 20130226; CZ 20013434 A 20000324; DK 09175437 T 20000324; EP 00918396 A 20000324; EP 09175437 A 20000324; EP 10180107 A 20000324; EP 10180283 A 20000324; ES 09175437 T 20000324; HK 10108446 A 20100906; HU P0200575 A 20000324; IL 14513400 A 20000324; IL 14513401 A 20010827; IL 20702910 A 20100715; JP 2000606632 A 20000324; JP 2011161258 A 20110722; JP 2014026148 A 20140214; KR 20017012238 A 20010925; KR 20067020750 A 20061002; KR 20107002138 A 20000324; KR 20127020122 A 20000324; KR 20137024212 A 20000324; KR 20147017491 A 20000324; LU 92159 C 20130227; MX PA01009645 A 20000324; MY PI20001172 A 20000324; MY PI20064253 A 20000324; NO 20014605 A 20010921; NO 20131482 A 20131107; NO 2014024 C 20140918; NZ 51394500 A 20000324; NZ 52957100 A 20000324; NZ 59255000 A 20000324; NZ 59672300 A 20000324; NZ 61156300 A 20000324; PL 35184200 A 20000324; PL 40983900 A 20000324; PT 09175437 T 20000324; SI 200031074 T 20000324; SK 13672001 A 20000324; TR 200102715 T 20000324; TR 200501367 T 20000324; TR 200503572 T 20000324; TR 200603997 T 20000324; TR 200802278 T 20000324; TW 100149356 A 20000918; TW 101120051 A 20000918; TW 89105501 A 20000918; TW 95145663 A 20000918; TW 99128334 A 20000918; ZA 200107774 A 20010920